Key Questions 1. For outpatients with depressive, anxiety, and/or premenstrual dysphoric disorders, do second-generation antidepressants differ in efficacy or effectiveness? 2. For outpatients with depressive, anxiety, and/or premenstrual dysphoric disorders, do second-generation antidepressants differ in harms or adverse events? 3. Are there subgroups of patients based on demographics (age, racial groups, socio-demographic factors, and sex), other medications, or comorbidities for which one second-generation antidepressant is more effective or associated with fewer adverse events than another?
|Duration||01/07/2009 - 31/03/2011|
|Principle investigator for the project (Danube University Krems)||Univ.-Prof Dr. Gerald Gartlehner, MPH|
|Project members||Dr. Angela Kaminski-Hartenthaler Mag. Christina Kien Michaela Strobelberger, MA Dipl.-Ing. Patricia Tüchler|
Gartlehner, G.; Reichenpfader, U.; Kaminski, A.; Kien, C.; Thaler, K. et. al. (2011). Drug Class Review: Second-generation Antidepressants: Final Update 5 Report. Oregon Health & Science University, http://www.ncbi.nlm.nih.gov/books/NBK54355/pdf/TOC.pdf